The following is a summary of “Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer: A Clinical ...

Merck will discontinue its antibody-drug Zinplava for a bacterial infection that can lead to fatal diarrhea, according to the ...

Inflammatory breast cancer is a rare type of cancer which progresses rapidly Read this article to know its symptoms diagnosis ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

A Fremont pharmaceutical company received an investment of approximately $50 million in a private placement from Merck & Co.

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Craig shouldn’t be alive to tell his story, in fact, he should have died three years ago, but a wonder drug dragged him back ...

With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, ...

Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to ...

Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for ...